Skip to main content
Clinical Trials/IRCT2014102619678N1
IRCT2014102619678N1CompletedPhase 1

Efficacy of fluoroquinolones in treating interferon non-responders infected with HCV genotype 3a

Higher Education Commission, Pakistan0 sites40 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Sponsor
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
25 years to 60 years (—)
Sex
All

Inclusion Criteria

  • Patient on IFN treatment who have not shown two-log reduction in their HCV load for 3 months
  • HCV-RNA positive
  • Infection with HCV genotype 3a
  • Chronic hepatitis diagnosed by liver ultrasound
  • Pre-cirrhotic, as determined by liver ultrasound
  • Informed consent to participate in the study
  • Exclusion criteria:
  • Known hypersensitivity to fluoroquinolones
  • Infection with HCV genotype other than 3a
  • Pregnant females
  • Concurrent hepatitis B or HIV infection
  • Carcinomatous changes on liver biopsy evident in liver ultrasound
  • History of alcohol or intravenous drug abuse
  • Disinclination to informed consent

Exclusion Criteria

  • Not provided

Investigators

Sponsor
Higher Education Commission, Pakistan

Similar Trials